About Cevena Bioproducts
Cevena aims to improve human health and well-being through the research, technology and marketing of scientifically sound, superior nutraceutical. The company's lead product Viscofiber(R) high beta-glucan concentrate is derived from oats and barley via a patented fractionation process that yields a rich, high quality beta- glucan ingredient.
Missing: Cevena Bioproducts's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: Cevena Bioproducts's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Expert Collections containing Cevena Bioproducts
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Cevena Bioproducts is included in 1 Expert Collection, including Vitamin & Supplement Startups.
Vitamin & Supplement Startups
Latest Cevena Bioproducts News
Jan 25, 2018
Cevena Bioproducts Announces $6 Million in Financing Tuesday, June 28, 2005 Funding to help launch key heart-health ingredient EDMONTON, Alberta, June 28 /CNW Telbec/ - Kimmo Lucas, President and CEOof Cevena Bioproducts, Inc., has announced that the company has securedfunding in the amount of $6.0 million, one of the largest health and nutritionfinancings in Canada this year. According to Lucas, the funds will ensure Cevena's successfulcommercialization of Viscofiber(R), the highest quality beta-glucanconcentrate available to the food and dietary supplement markets. This novel,clinically proven ingredient offers unsurpassed heart-health and satietybenefits to the supplement and food markets. Viscofiber(R) is Cevena's leadproduct that was recently launched in the United States. "Cevena's coremission is to improve human health through effective, scientifically provenproducts," Lucas says. "Our customers expect superior quality research, strongpatent protection and marketing support with outstanding quality, 'a given. 'This investment enables us to continue to exceed expectations and to provideconsumers with a safe, effective and convenient means of keeping themselvesheart-healthy." The Business Development Bank of Canada's Venture Capital Group led theround and was joined by Golden Opportunities Fund (Saskatoon, Sask). Thesyndicate also included existing investors Foragen Technologies, Inc(Saskatoon, Sask) and AVAC, Ltd. (Calgary, AB). Lucas notes that theseinvestors "were chosen based upon their expertise in the agri-food/supplementarea as well as the synergies they bring to Cevena Bioproducts and ourflagship technology employed to produce our lead product, Viscofiber(R)." "We are excited to be working with a company with management of thiscaliber, and to have the opportunity to invest in the rapidly growing field ofscience-based natural ingredients for the health and nutrition markets," saysGary Bantle, Director, Life Sciences at BDC Venture Capital. "Cevena isclearly representative of the dynamic and leading edge companies in which BDCinvests and we are pleased to have led this round of financing." "The leading edge technology in Cevena immediately grabbed ourattention," comments Grant Kook, CEO/Chairman of Golden Opportunities FundInc. We are now excited for management to move forward on its strategy withthis round of financing." About Cevena Bioproducts Inc. Technically advanced grain-based ingredients for nutritional products arethe focus of Cevena Bioproducts, headquartered in Edmonton, Alberta, Canadawith offices in Saskatoon, Saskatchewan. The company's core mission is toimprove human health and well-being through the research, technology andmarketing of scientifically sound, superior nutraceutical. Its lead productViscofiber(R) high beta-glucan concentrate is derived from oats and barley viaa patented fractionation process that yields the richest, highest quality beta-glucan ingredient on the market today. Viscofiber(R) is in clinical trials toprove its efficacy in addressing healthy cholesterol levels and maintaining ahealthy glycemic response for heart health-conscious consumers. Furtherclinical research will illuminate its efficacy for gastrointestinal health andsatiety. For more information, log on to www.cevena.com . About BDC Venture Capital BDC Venture Capital is a major venture capital investor in Canada, activeat every stage of the company's development cycle, from start-up throughexpansion, with a focus on technology-based business that have high growthpotential and that are poised to become dominant players in their markets. BDCVenture Capital has been involved in venture capital since 1975 and has todate invested in more than 400 different companies. It currently manages over$500 million in venture capital assets invested in life sciences,telecommunications, information technology and advanced technologies.www.bdc.ca /For further information: Kimmo Lucas, (780) 436-6002,kim.lucas(at)cevena.com/ © CNW Group
Cevena Bioproducts Frequently Asked Questions (FAQ)
Where is Cevena Bioproducts's headquarters?
Cevena Bioproducts's headquarters is located at 4244 Enterprise Square, Edmonton.
What is Cevena Bioproducts's latest funding round?
Cevena Bioproducts's latest funding round is Acquired.
Who are the investors of Cevena Bioproducts?
Investors of Cevena Bioproducts include Natraceutical Group, Foragen Technologies Management, Golden Opportunities Fund, BDC Venture Capital and AVAC.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.